title: XPA A23G polymorphism and lung cancer risk: a meta-analysis.
abstract: Case-control studies on the association between XPA A23G and lung cancer have provided either controversial or inconclusive results. To clarify the effect of XPA A23G on the risk of lung cancer, a meta-analysis of all case-control observational studies was performed. Pooled odds ratios (ORs) for various polymorphisms were estimated using random and fixed effects models. The Q-statistic was used to evaluate the homogeneity, and Egger and Begg tests were used to assess publication bias. For the homozygote GG and G allele carriers (GA + GG), the pooled ORs were 1.24 (95% CI 1.05-1.46; P = 0.27 for heterogeneity) and 1.30 (95% CI 1.13-1.51; P = 0.45 for heterogeneity) compared to the homozygous genotype (AA). In the stratified analysis by ethnicity, the ORs of the G allele carriers and the homozygote GG were 1.28 (95% CI 1.10-1.49; P = 0.07 for heterogeneity) and 1.42 (95% CI 1.04-1.93; P = 0.39 for heterogeneity) among non-Caucasians. No significant associations were found in the Caucasian population in any of the genetic models. When studies that were not in Hardy-Weinberg equilibrium (HWE) were corrected, the pattern of the results remained the same. Our results indicated a significantly decreased risk of lung cancer in non-Caucasians with the G allele.
authors: Department of Gerontology, The Affiliated Zhong Da Hospital of Southeast University, 87 Dingjiaqiao, Nanjing 210009, People's Republic of China.
authors: Ji-Hong
authors: JH
authors: Zou
authors: Li
authors: L
authors: An
authors: Shi
authors: S
authors: Chen
authors: Li-Qun
authors: LQ
authors: Ren
references: Mutat Res. 2007 Mar 1;616(1-2):221-6
references: 17161851
references: Mutat Res. 2007 Jul 28;631(2):101-10
references: 17531525
references: Genet Med. 2002 Mar-Apr;4(2):45-61
references: 11882781
references: Carcinogenesis. 2003 Mar;24(3):505-9
references: 12663511
references: Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):993-7
references: 12376498
references: Br Med J. 1952 Dec 13;2(4797):1271-86
references: 12997741
references: Mol Cell Biol. 1995 Oct;15(10):5396-402
references: 7565690
references: Cancer Cell. 2002 Feb;1(1):49-52
references: 12086887
references: Epidemiology. 1997 Nov;8(6):653-7
references: 9345665
references: Mayo Clin Proc. 2008 May;83(5):584-94
references: 18452692
references: Br Med J. 1976 Dec 25;2(6051):1525-36
references: 1009386
references: J Biol Chem. 2001 May 4;276(18):15434-40
references: 11278856
references: J Clin Oncol. 2008 Jul 20;26(21):3560-6
references: 18640936
references: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30
references: 12496039
references: Am J Public Health. 1987 Apr;77(4):425-31
references: 3826460
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Hum Mutat. 2000 Jun;15(6):577-8
references: 10862089
references: Cancer Res. 1996 Sep 15;56(18):4103-7
references: 8797573
references: Nat Rev Cancer. 2004 Nov;4(11):850-60
references: 15516958
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Carcinogenesis. 2006 Mar;27(3):560-7
references: 16195237
references: Carcinogenesis. 2004 Dec;25(12):2433-41
references: 15333465
references: Genomics. 2004 Jun;83(6):970-9
references: 15177551
references: Lung Cancer. 2008 Feb;59(2):171-9
references: 17913280
references: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3081-9
references: 18990748
references: Cancer Lett. 2005 May 10;222(1):67-74
references: 15837542